Haematologica @Haematologica Twitter profile

Last Seen Profiles

@a_zeynepardic

@trhk206

@PasutriAsli2

@teikoku_mikad0

@blurredcanvas

@SolGaschetto

@celldweller

@RatriLove1

@ZDhOvzkMkWtesdV

@Gabyychamo

@Homes907

@Anglsti

@StarlitBallad

@SksQss

@BznsMram

@Informatio90536

@DrNidhiKataria

@JavAdultt

@CezarJinga

@paper_message

@BrickinfoReport

@MmOltoOfficial

@APEC_CEOsummit

@FederalistPress

@makemeamistake

@FlavorsNasty

@whostayswift

@zerkzfv

@jazibah53234577

@sasamomimomi

@oudi_piperrak

@Siya28297121

@VeryPinkKnight

@4atnun

@shar1z

@Tsuki2167

Haematologica

@Haematologica

1 year

Maintenance therapy in #AcuteMyeloidLeukemia (AML) is a new approach towards preventing relapse. In this review, the authors comprehensively discuss the development of #AML #maintenance therapy over the last 3 decades.

2

75

182

Haematologica

@Haematologica

9 months

The crazy case of a #T -cell ALL that switched to acute myeloid leukemia shortly after #CART -cellTherapy targeting #CD7 . #Myeloid switch could be a new escape mechanism of leukemia under the pressure of targeting CD7.

4

60

171

Haematologica

@Haematologica

7 months

Review Article: #largeB -cellLymphoma ( #DLBCL ) involving the central nervous system represents a clinical challenge. Read here advances in the molecular pathogenesis and biological rationale for targeted therapy.

0

57

160

Haematologica

@Haematologica

9 months

#PeripheralT -CellLymphoma: read here the introduction to the review series and the focus on the new refinement in classification and molecular characterization, with the best and most innovative treatment options.

0

65

146

Haematologica

@Haematologica

2 years

In this issue of Haematologica, within a review series on #AcuteMyeloidLeukemia , Stelmach and Trumpp discusses leukemic stem cell biology and associated resistance mechanisms.

2

38

127

Haematologica

@Haematologica

1 year

Grade 3B follicular lymphoma: read here the results of the first large international study on prognosis, outcomes and relapse patterns of this rare #FollicularLymphoma subtype in the rituximab era.

0

39

96

Haematologica

@Haematologica

4 years

The molecular landscape of inherited #thrombocytopenias : major steps in the current understanding of these conditions and recent advances.

0

38

94

Haematologica

@Haematologica

6 years

Two immune escape strategies of lymphoma: lymphoma cells may “hide” to become invisible to the immune system or cells may “defend” themselves to become resistant to immune eradication. Knowing these mechanisms helps to determine the optimal immunotherapy

1

50

87

Haematologica

@Haematologica

4 years

This review provides a comprehensive overview of the current status of the clinical evaluation, biology and therapeutic interventions for #myelodysplasticSyndrome .

0

35

81

Haematologica

@Haematologica

2 years

In this issue of Haematologica, within a review series on #AcuteMyeloidLeukemia (AML), Sabine Kayser and Mark J. Levis review the clinical impact of the molecular landscape of AML.

0

24

74

Haematologica

@Haematologica

9 months

#PeripheralT -CellLymphoma: read the new review about the pathology and biology of nodal-based #PTCL entities, with an emphasis on recent findings and underlying oncogenic mechanisms.

0

29

72

Haematologica

@Haematologica

10 months

In this issue of Haematologica, a new study explores the transcriptome features of acute #promyelocytic -like leukemia cases lacking #RAR rearrangements.

0

19

71

Haematologica

@Haematologica

8 months

#Tagraxofusp : the first #CD123 -targetedagent and the first drug specifically approved for #blasticplasmacytoiddendriticcellneoplasm . A new review on its development, preclinical insights, clinical data, and toxicity.

1

21

70

Haematologica

@Haematologica

4 years

Herein, the Authors review the current understanding of #CD20function , and the mechanisms of its regulation in normal and malignant #Bcells , highlighting the therapeutic implications.

1

35

71

Haematologica

@Haematologica

10 months

Read here a new #SpotlightReview on the new #JAK2inhibitor #momelotinib : mechanism of action, clinical reports and therapeutic prospects, including a risk-adapted treatment approach in #primarymyelofibrosis .

0

18

69

Haematologica

@Haematologica

3 years

#R /RFollicularLymphoma: when and how to utilize the growing array of therapies at our disposal.

0

20

67

Haematologica

@Haematologica

2 years

In a review article James B. Bussel and Christine A. Garcia summarizes their approach to the diagnosis of #immuneThrombocytopenia , its secondary forms, and choice of second-line treatment options.

0

19

66

Haematologica

@Haematologica

1 year

Read here about the impact of additional genetic abnormalities in #CML patients treated with first-line imatinib.

0

20

66

Haematologica

@Haematologica

7 months

Read here results of a new study on a #ruxolitinib -based regimen as a bridge to transplant for #primaryHemophagocyticLymphohistiocytosis .

0

28

62

Haematologica

@Haematologica

4 years

The molecular basis for the prothrombotic state in #SCD : activation of overlapping inflammation and coagulation pathways that predispose to #VenousThromboembolism ..

0

31

62

Haematologica

@Haematologica

10 months

What is the effect of B-lineage #acuteLymphoblasticLeukemia ( #B -ALL ) on residual normal hematopoiesis? A new murine #B -ALL model shows premature aging of “leukemia-exposed” hematopoietic stem cells.

0

12

59

Haematologica

@Haematologica

1 year

In this issue of Haematologica, Chen et al.describe mechanisms by which monoclonal gammopathy (MG) can cause tissue damage and review the literature and the case for MG screening.

0

20

61

Haematologica

@Haematologica

5 years

This review summarizes the current knowledge regarding somatic mutations in AML, their contribution to clonal fitness under different selective environmental conditions, and their correlation with patients’ clinical outcomes. #mutation #AML

1

37

60

Haematologica

@Haematologica

1 year

Do prognostic tools for older patients with #DiffuseLargeB -cellLymphoma ( #DLBCL ) need to be optimized? The Geriatric Prognostic Index is the answer.

1

20

59

Haematologica

@Haematologica

9 months

#PeripheralT -CellLymphoma. Review of the clinical management of rare subtypes: #SubcutaneousPanniculitis -likeT-cellLymphoma, #hepatosplenic , and #intestinalT -cellLymphoma, and #extranodalNK /T-cellLymphoma.

0

24

58

Haematologica

@Haematologica

4 years

This review highlights clinical and molecular aspects in the approach to patients with Glanzmann thrombasthenia, with particular emphasis on the significance of multidisciplinary care.

0

26

58

Haematologica

@Haematologica

11 months

Read here a new review on the management of #DownSyndrome patients with #leukemia : what is known, key questions in the field, and challenges.

0

24

58

Haematologica

@Haematologica

1 year

New applications of #ArtificialIntelligence in hematology to improve the diagnosis and classification of #MyelodysplasticSyndromes

0

14

56

Haematologica

@Haematologica

4 years

#BCR -ABL1-like #AcuteLymphoblasticLeukemia in childhood and targeted therapy: a perspective article.

0

20

54

Haematologica

@Haematologica

11 months

Measurable residual disease can guide treatment strategy in intermediate-risk #acuteMyeloidLeukemia patients: detailed analysis of the results of the HO132 trial.

0

14

56

Haematologica

@Haematologica

10 months

#LandmarkPaper : the International Prognostic Index (IPI), published in 1993 for patients with aggressive B-cell lymphoma, is still the standard for patient prognostication today.

1

16

54

Haematologica

@Haematologica

1 year

#LandmarkPaper : in the treatment of advanced stage aggressive lymphomas, the iconic S8516/0067 trial established #CHOP as a formidable therapeutic backbone that has proved difficult to replace

0

28

54

Haematologica

@Haematologica

5 months

A new review explores the physiology and physiopathology of #D -dimer formation and summarizes the main conditions associated with increased D-dimer while proposing a new approach to their management.

0

14

54

Haematologica

@Haematologica

8 months

Treatment of patients with secondary #acutemyeloidleukemia ( #AML ) and AML with myeloid-related changes in patients aged 60 to 75 years is still challenging. Read results and outcomes from the #PETHEMA registry.

1

16

52

Haematologica

@Haematologica

5 years

Herein, are reviewed methods of minimal residual disease (MRD) detection and the prognostic impact of MRD across AML subtypes. Can MRD guide post-remission treatment decisions in AML? #MRD #AML #treatment

0

31

51

Haematologica

@Haematologica

4 years

Combined inhibition of #MDM2 and #BCR -ABL1 tyrosine kinase can target #CML cells and CML stem/progenitor cells, and it has the potential to improve outcomes in CML.

0

21

52

Haematologica

@Haematologica

2 years

The outcome of #CBF -AML patients with #FLT3 -ITD may be inferior to that of patients without #FLT3 -ITD, suggesting that prognostically #CBF -AML patients with #FLT3 -ITD should not be classified as favorable-risk.

2

16

52

Haematologica

@Haematologica

5 months

Here, Cournoyer and colleagues describe their experience with the #BRAF -inhibitor dabrafenib and the #MEK -inhibitor trametinib to treat patients with newly diagnosed or relapsed/refractory #Langerhans_cell_histiocytosis .

0

21

52

Haematologica

@Haematologica

3 years

The characteristics and outcome of patients who received #daratumumab “off label” (compassionate use) for severe refractory #ITP or warm #AIHA : an observational, retrospective study.

0

7

50

Haematologica

@Haematologica

4 years

Haematologica celebrates its 100th birthday with an Atlas that collects cytological pictures concerning all the main hematologic diseases

0

27

50

Haematologica

@Haematologica

5 months

The appearance of #TP53_mutation in #myelodysplastic_syndrome with #del (5q) with #lenalidomide treated with #lenalidomide is a well-known event, but what happens after salvage with decitabine? The case of a 75-year-old man with #MDS del(5q).

2

11

49

Haematologica

@Haematologica

4 years

This review describes key advances in our understanding of the biology of ALL and optimal approaches to risk-stratification and therapy, and it suggests key areas for basic and clinical research.

0

22

50

Haematologica

@Haematologica

10 months

#BispecificT -cellEngagers ( #BiTE ) targeting #B -cellMaturationAntigen ( #BCMA ) have resulted in unprecedented response rates in R/R multiple myeloma, but viral infections are the flipside: an educational three case series.

0

21

47

Haematologica

@Haematologica

7 months

#LandmarkPaper : in 1988, with a new publication in Blood, the history of the treatment of #acutePromyelocyticLeukemia . The authors reported stunning results with the oral vitamin derivative #all -transRetinoicAcid ( #ATRA ).

0

15

47

Haematologica

@Haematologica

3 years

In #AML , #RNA -sequencing has a strong potential to improve the systematic detection of fusion genes and provides a valuable tool for fusion discovery.

0

19

48

Haematologica

@Haematologica

5 years

Minimal residual disease (MRD) is an important prognostic factor in AML. The Authors focus on the therapies that have been developed for each target and evidence of efficacy in reducing MRD prior to allo-SCT. #MRD #AML #therapy

1

26

46

Haematologica

@Haematologica

3 years

The New Impact Factor of Haematologica: 9.941

0

2

47

Haematologica

@Haematologica

9 months

#PeripheralT -CellLymphoma: a new review about therapeutic approaches in nodal #PeripheralT -CellLymphoma. The backbone and future directions for first-line and relapsed/refractory settings.

0

12

45

Haematologica

@Haematologica

1 year

In this issue of Haematologica, Bobillo and colleagues review the prevention and management of #secondaryCNSLymphoma .

0

23

45

Haematologica

@Haematologica

6 years

The data presented in this article by Guy et al. provide evidence that JAK2V617F-expressing endothelial cells promote thrombosis through induction of endothelial P-selectin expression, which can be reversed by hydroxyurea

1

26

44

Haematologica

@Haematologica

4 years

T-cell-mediated aGvHD development: the roles that specific epigenetic regulators play and how their modulation could disrupt that process with beneficial effects.

0

16

46

Haematologica

@Haematologica

9 months

#PeripheralT -CellLymphoma: clinical and pathogentic features of primary #intestinalT -cellLymphoma and #NK -cellNeoplasms, #extranodalNK /T-cellLymphoma, #hepatosplenic , #nasaltype , and SubcutaneousPanniculitis-likeT-cellLymphoma

0

9

46

Haematologica

@Haematologica

3 years

January 2022 issue is available online. See and download for free the Haematologica Digital Edition!

0

10

44

Haematologica

@Haematologica

10 months

Read here a new review about the #bortezomib , and #dexamethasone regimen, a new backbone of treatment for #newlydiagnosedmultiplemyeloma .

1

11

45

Haematologica

@Haematologica

4 months

In this issue of Haematologica, a new study identified a novel potential therapeutic target for B-ALL: the mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1).

1

14

44

Haematologica

@Haematologica

7 months

A new method to overcome the problem of the presence of clonal hematopoiesis when detecting measurableResidualDisease ( #MRD ) in acute myeloid leukemia through #Next -generationSequencingBased ( #NGS ) techniques.

0

15

43

Haematologica

@Haematologica

5 years

The crosstalk between hematopoietic stem cells and the microenvironment is indispensable for the aging of the hematopoietic system and might represent a therapeutic target in age-related pathological disorders.

0

22

44

Haematologica

@Haematologica

11 months

#CART -cell treatment of high-risk multiple myeloma: Who can benefit from it? Who cannot? A new meta-analysis summarizes the current body of evidence on the role of novel #CART -cell therapies in this setting of patients.

0

10

42

Haematologica

@Haematologica

2 years

Richard Schlenk introduces the review series on #AcuteMyeloidLeukemia published in this issue of Haematologica.

0

15

43

Haematologica

@Haematologica

1 year

Hematologic toxicities are highly under-reported adverse events (AE) in #CART -cellTherapy clinical trials. An analysis of the CAR T-associated hematologic AE using the US Food and Drug Administration AE Reporting System (FAERS).

0

12

42

Haematologica

@Haematologica

8 months

January 2024 issue is available online. See and download for free the Haematologica Digital Edition!

0

7

43

Haematologica

@Haematologica

1 year

In this issue of Haematologica, Zhang et al. identified autophagy as one of the resistance mechanisms of FLT3-targeted therapy, and they test a novel multikinase inhibitor CG-806 (luxeptinib) in FLT3-mutated AML.

0

8

43

Haematologica

@Haematologica

2 years

In this review, Mrinal M. Patnaik discusses his approach to the diagnosis, prognosis, and management of patients with CMML.

1

12

40

Haematologica

@Haematologica

6 months

A new study on the characterization of the B-cell receptor of monoclonal B lymphocytosis in siblings of patients with #chronicLymphocyticLeukemia ( #CLL ) provides insights into the early steps of the development of CLL.

2

19

41

Haematologica

@Haematologica

9 months

A study on conditional outcome and proportional mortality of patients with severe aplastic anemia surviving at one year after treatment allows risk-adapted interventions tailored to the change in mortality risk in survivors over time.

0

10

39

Haematologica

@Haematologica

9 months

#NodularLymphocyte -predominantHodgkinLymphoma is a Hodgkin lymphoma expressing functional #B -cellReceptors. The bacterium #RothiaMucilaginosa is a new key factor in the disease pathogenesis of this rare lymphoma.

0

19

42

Haematologica

@Haematologica

10 months

November 2023 issue is available online. See and download for free the Haematologica Digital Edition!

1

8

42

Haematologica

@Haematologica

4 months

Quantification of home time (HT) among older adults with acute myeloid leukemia (AML) following diagnosis: HT is quantified after intensive and non-intensive treatment strategies, with surprising and unexpected results.

0

10

41

Haematologica

@Haematologica

3 years

Here, Svanberg et al. review the current knowledge on how novel targeted therapies modulate #CLL -tumor microenvironment cells and their interactions.

0

14

41

Haematologica

@Haematologica

9 months

The development of childhood #B -cellAcuteLymphoblasticLeukemia seems to follow a two-step model: genetic and environmental. Can pinworms be the environmental step? Read here the new study by Fith and colleagues.

0

13

42

Haematologica

@Haematologica

2 years

In this issue of Haematologica, within a review series on on #measurableResidualDisease ( #MRD ), Blachly and colleagues review the current approaches to #MRD testing in #acuteMyeloidLeukemia .

0

13

41

Haematologica

@Haematologica

1 year

A new review provides an overview of the progress made in the treatment of #pediatricPatients with relapsed #AML and highlights state-of-the-art therapeutic approaches adopted in new and ongoing clinical investigation.

0

8

32

Haematologica

@Haematologica

6 months

Are androgens still an option for the treatment of acquired or inherited #boneMarrowFailure ? Results of the study of the largest international cohort which tracked current real-life use, indications, efficacy, toxicity, and long-term effects.

0

18

40

Haematologica

@Haematologica

11 months

Red cell synthesis and iron metabolism: a new review summarizes their mechanisms and describes potential therapeutics alone or in combination and their current uses on various diseases.

0

15

40

Haematologica

@Haematologica

6 years

A review on the unique morphological, immunophenotypic, and genetic characteristics of patients with CLL carrying +12.

1

21

36

Haematologica

@Haematologica

8 months

A new study unravels the role of hepatitis B virus in the pathogenesis of #multiplemyeloma ( #MM ) and monoclonal gammopathies of undetermined significance.

0

15

39

Haematologica

@Haematologica

3 years

Acalabrutinib is effective and tolerable in most patients with relapsed/refractory #chronicLymphocyticLeukemia who are intolerant of #ibrutinib .

0

7

38

Haematologica

@Haematologica

7 months

A new study investigates the genomic configuration of #BCL3 Rearrangements in #B -cellNeoplasms and unravels the clinical and biological significance of these alterations.

0

11

38

Haematologica

@Haematologica

4 years

In this narrative review the Authors summarize the most recent clinical evidence on the use of #TranexamicAcid ( #TXA ) for prevention or treatment of #bleeding .

0

23

38

Haematologica

@Haematologica

6 months

#Eculizumab and #ravulizumab , first-line treatments of #PNH ), inhibit the activity of complement component 5 (C5).

0

17

38

Haematologica

@Haematologica

2 years

Thalassemia was first described in 1925 by Cooley and Lee. In 1965 Weatherall et al. published their landmark paper revealing its causes and becoming the driving forces behind the development of molecular medicine.

1

13

37

Haematologica

@Haematologica

6 months

Ibrutinib represents a new backbone in the treatment strategy of #chronicLymphocyticLeukemia ( #CLL ). A new study elucidates the mechanism by which ibrutinib causes a rapid redistribution of CLL cells from lymphoid tissues to peripheral blood.

0

5

38

Haematologica

@Haematologica

6 years

HBV reactivation is not uncommon in patients with hematologic disorders and malignancies, and ongoing reports of significant morbidity, or even fatalities, make this an important topic to understand and manage appropriately

0

14

38

Haematologica

@Haematologica

3 years

Here, Bruno et al. critically review the most important pre-clinical and clinical findings, recent advances in #CAR -T against #myeloma , as well as discoveries in the biology of a still incurable disease.

0

17

37

Haematologica

@Haematologica

2 years

Khwaja and colleagues present a review article to #IgMMonoclonalGammopathy of clinical significance with the aim of providing a practical guidance of diagnosis and treatment.

0

15

34

Haematologica

@Haematologica

3 years

This review discusses recent progress in the erythroid culture field as well as opportunities for further scaling up of manufactured #RBC production for transfusion practice.

0

14

35

Haematologica

@Haematologica

5 years

The clinical hematologist must be aware of imperfect accuracy when using only red cell values for distinguishing essential thrombocythemia JAK2V617F from PV.

0

15

34

Haematologica

@Haematologica

4 years

aGvHD pathogenesis, microbiota dysbiosis, and the development of aGvHD biomarkers.

0

11

35

Haematologica

@Haematologica

9 months

December 2023 issue is available online. See and download for free the Haematologica Digital Edition!

0

10

35

Haematologica

@Haematologica

5 years

The first EBMT ad JACIE recommendations for the management of adults and children undergoing CAR T cell therapy.

0

25

34

Haematologica

@Haematologica

4 years

#CSF #ctDNA can detect #CNS lesions better than plasma #ctDNA and flow-cytometry and it can predict #CNS relapse in #CNS and systemic lymphomas.

0

14

35

Haematologica

@Haematologica

1 year

In this issue of Haematologica, Xiang Zhou and colleagues review the loss of #B -cellMaturationAntigen ( #BCMA ) in the new era of immunotherapy for #multipleMyeloma .

0

11

34

Haematologica

@Haematologica

5 years

Next Generation Sequencing (NGS) at diagnosis is essential for accurate risk stratification of AML patients according to the 2017 ELN recommendations and has now been implemented in many molecular diagnostic laboratories. #NGS #AML #ELN

2

19

35

Haematologica

@Haematologica

8 months

#MeasurableResidualDisease and #acutemyeloidleukemia ( #AML ). A new study about the influence of baseline features and treatment intensity on the predictive value of an measurable residual disease-negative status on relapse-free and overall survival.

0

5

33

Haematologica

@Haematologica

5 years

A comprehensive evidence-based approach to the diagnosis and management of Philadelphia-chromosome-like ALL at different time-points during the disease course.

0

19

32

Haematologica

@Haematologica

1 year

Autoimmune hemolytic anemia is a challenging complication in #ChronicLymphocyticLeukemia . Excellent results from Venetoclax-Rituximab combination in two Spanish patients.

1

10

33

Haematologica

@Haematologica

3 years

This study suggests that #CD33 #SNP #rs12459419 is one of the predictive factors that affects the rate of relapse in patients with #NPM1 -mutated #AML receiving GO.

1

11

33

Haematologica

@Haematologica

5 years

Sequential and combined use of novel agents in CLL: advantages and drawbacks of these two approaches.

0

14

31

Haematologica

@Haematologica

1 year

October 2023 issue is available online. See and download for free the Haematologica Digital Edition!

0

7

32

Haematologica

@Haematologica

6 years

Dexamethasone may improve acute myeloid leukemia patients receiving intensive chemotherapy. This effect could be due to the modulation of inflammatory chemoresistance pathways and to a specific activity in acute myeloid leukemia with NPM1 mutation

0

24

33